NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)

被引：1
|
作者：
De Vincenzo, F.
Rossoni, G.
Santoro, A.
Gregorc, V.
Zucali, P. A.
Citterio, G.
Simonelli, M.
Petrella, G.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
机构：
[1] Humanitas Canc Ctr, Rozzano, Italy
[2] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[3] MolMed SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7089
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study
    Gregorc, V.
    Ceresoli, G. L.
    Zucali, P. A.
    De Braud, F. G.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 509 - 509
  • [2] NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM)
    Rossoni, Gilda
    Gregorc, Vanesa
    Vigano, Maria Grazia
    Bulotta, Alessandra
    Ghio, Domenico
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM)
    Gregorc, V.
    Ceresoli, G. L.
    Zucali, P. A.
    De Braud, F. G.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM)
    Gregorc, V.
    Gaafar, R.
    Favaretto, A.
    Grossi, F.
    Jassem, J.
    Polychronis, A.
    Bidoli, P.
    Tiseo, M.
    O'Brien, M.
    Shah, R.
    Taylor, P.
    Novello, S.
    Muzio, A.
    Bearz, A.
    Badurak, P.
    Greillier, L.
    Fontana, F.
    Colombi, S.
    Lambiase, A.
    Bordignon, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S634 - S634
  • [5] Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).
    Gaafar, Rabab M.
    Favaretto, Adolfo G.
    Gregorc, Vanesa
    Grossi, Francesco
    Jassem, Jacek
    Polychronis, Andreas
    Bidoli, Paolo
    Tiseo, Marcello
    O'Brien, Mary E. R.
    Shah, Ryaz
    Taylor, Paul
    Novello, Silvia
    Muzio, Alberto
    Bearz, Alessandra
    Badurak, Pawel
    Greillier, Laurent
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015.
    Gregorc, Vanesa
    Vigano, Maria G.
    Bulotta, Alessandra
    Citterio, Giovanni
    Petrella, Giovanna
    Brioschi, Elena
    Ducceschi, Monika
    Gianni, Luca
    Colombi, Scialini
    Rossoni, Gloria
    Salini, Giulia
    Redaelli, Emma
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3
    Gregorc, Vanesa
    Gaafar, Rabab M.
    Favaretto, Adolfo
    Grossi, Francesco
    Jassem, Jacek
    Polychronis, Andreas
    Bidoli, Paolo
    Tiseo, Marcello
    Shah, Riyaz
    Taylor, Paul
    Novello, Silvia
    Muzio, Alberto
    Bearz, Alessandra
    Greillier, Laurent
    Fontana, Floriana
    Salini, Giulia
    Lambiase, Antonio
    O'Brien, Mary
    LANCET ONCOLOGY, 2018, 19 (06): : 799 - 811
  • [8] PHASE II CLINICAL TRIAL OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), AS SECOND-LINE THERAPY IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Ceresoli, G. L.
    Gregorc, V.
    Zucali, P. A.
    Noberasco, C.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 119
  • [9] Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM).
    Gregorc, Vanesa
    Bulotta, Alessandra
    Vigano, Maria G.
    Citterio, Giovanni
    Petrella, Giovanna
    Brioschi, Elena
    Ducceschi, Monika
    Gianni, Luca
    Colombi, Scialini
    Rossoni, Gloria
    Salini, Giulia
    Savia, Veronica
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
    Gregorc, V.
    Bulotta, A.
    Vigano, M. G.
    Citterio, G.
    Petrella, G.
    Brioschi, E.
    Ducceschi, M.
    Gianni, L.
    Colombi, S.
    Rossoni, G.
    Salini, G.
    Savia, V.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2016, 27
12345